文献速递糖尿病

2型糖尿病患者起始SGLT2抑制剂与GLP-1受体激动剂后泌尿生殖系统感染风险:丹麦队列研究

Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2is Versus GLP-1RAs in Routine Clinical Care: A Danish Cohort Study.
PubMed 文献 · Diabetes Care · 2025-01-01

在丹麦2016-2021年起始SGLT2抑制剂或GLP-1受体激动剂的成人二甲双胍使用者中,采用模拟目标试验的队列设计及逆概率治疗加权平衡混杂因素。SGLT2抑制剂组52,414例,GLP-1受体激动剂组27,023例,中位随访2.9至3.9年。结果显示起始SGLT2抑制剂与泌尿系统感染风险增加无关,但生殖系统感染早期风险最高约三倍。

要点

  • 起始SGLT2抑制剂者1年泌尿系统感染风险10.0%,与GLP-1受体激动剂者10.2%接近,风险比0.98(95%CI 0.94, 1.03)。
  • 起始SGLT2抑制剂者1年生殖系统感染风险2.0%,高于GLP-1受体激动剂者0.7%,风险比2.95(95%CI 2.52, 3.44)。
  • 5年随访期间泌尿系统感染相对风险几乎恒定(0.96,95%CI 0.94, 0.99),生殖系统感染风险比降至1.64(95%CI 1.49, 1.80)。

核心结论

  • 在常规临床实践中,与起始GLP-1受体激动剂相比,起始SGLT2抑制剂与泌尿系统感染风险增加无关。
  • 然而,SGLT2抑制剂使用者的早期生殖系统感染风险最高约三倍。

研究设计与样本

  • 本研究为模拟目标试验的队列研究,纳入丹麦2016-2021年所有起始SGLT2抑制剂或GLP-1受体激动剂的成人二甲双胍使用者。
  • 采用逆概率治疗加权平衡潜在混杂因素,共纳入52,414例SGLT2抑制剂起始者和27,023例GLP-1受体激动剂起始者,中位随访2.9至3.9年。

主要发现

  • 意向性治疗分析中,起始SGLT2抑制剂者1年内泌尿系统感染估计风险为10.0%,GLP-1受体激动剂者为10.2%,风险比0.98(95%CI 0.94, 1.03)。
  • 起始SGLT2抑制剂者1年内生殖系统感染风险为2.0%,GLP-1受体激动剂者为0.7%,风险比2.95(95%CI 2.52, 3.44)。
  • 5年随访期间,泌尿系统感染相对风险几乎恒定(0.96,95%CI 0.94, 0.99),而SGLT2抑制剂的生殖系统感染风险比降至1.64(95%CI 1.49, 1.80)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Anticipated risks of urinary tract infections (UTI) and genital tract infections (GTI) associated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) may prevent their use in clinical practice. We investigated whether initiation of SGLT2is, compared with glucagon-like peptide 1 receptor agonists (GLP-1RAs), was associated with an elevated risk of UTI and GTI in people with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this cohort study emulating a target trial, we included all adult metformin users initiating SGLT2is or GLP-1RAs in Denmark in 2016-2021 and used inverse-probability of treatment (IPT) weighting to balance potential confounders. We estimated IPT-weighted risk and risk ratios of community- or hospital-treated UTI and GTI, performing both intention-to-treat and on-treatment analyses. RESULTS: This study included 52,414 SGLT2i initiators and 27,023 GLP-1RA initiators with a median follow-up of 2.9 to 3.9 years. The estimated risks of UTI within the first year were nearly identical: 10.0% for SGLT2is and 10.2% for GLP-1RAs in intention-to-treat analyses corresponding to a risk ratio of 0.98 (95% CI 0.94, 1.03). For GTI, the 1-year risks were elevated under SGLT2i therapy at 2.0% vs. 0.7% (risk ratio 2.95 [95% CI 2.52, 3.44]). During the 5-year follow-up, the relative UTI risk remained almost constant (0.96 [95% CI 0.94, 0.99]) whereas the GTI risk ratio with SGLT2is decreased to 1.64 (95% CI 1.49, 1.80). CONCLUSIONS: In routine clinical care, SGLT2i initiation is not associated with increased risk of UTI compared with GLP-1RA initiation. However, early GTI risk is up to threefold larger in SGLT2i users.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ljungberg C, Kristensen FPB, Dalager-Pedersen M, et al. Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2is Versus GLP-1RAs in Routine Clinical Care: A Danish Cohort Study. Diabetes Care. 2025. PMID: 40173095. doi:10.2337/dc24-2169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。